An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced that President and CEO Eric Shaff will be participating in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. The chat will be available for on-demand viewing on the company’s website. Seres is at the forefront of microbiome therapeutics, with its SER-109 program achieving positive pivotal clinical results for treating recurrent C. difficile infection and receiving FDA Breakthrough Therapy designation. The company is also advancing additional programs for ulcerative colitis and gastrointestinal infections.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, participated in a pre-recorded fireside chat as part of the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will take place November 29 – December 2, 2021. The fireside chat will be available for on-demand viewing on the Seres website.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study to address gastrointestinal infections, bacteremia and graft-versus-host disease. For more information, please visit www.serestherapeutics.com.
What is Seres Therapeutics, Inc. (MCRB) known for?
Seres Therapeutics, Inc. (MCRB) is known for developing microbiome therapeutics, particularly its SER-109 program for treating recurrent C. difficile infection.
When is the Piper Sandler Virtual Healthcare Conference taking place?
The Piper Sandler Virtual Healthcare Conference is scheduled from November 29 to December 2, 2021.
Where can I watch the fireside chat featuring Eric Shaff?
The fireside chat featuring Eric Shaff will be available for on-demand viewing on the Seres Therapeutics website.
What designations has the SER-109 program received?
The SER-109 program has received Breakthrough Therapy and Orphan Drug designations from the FDA.
What other studies is Seres Therapeutics currently conducting?
Seres Therapeutics is conducting Phase 1b studies for SER-301 in ulcerative colitis and SER-155 for gastrointestinal infections and other conditions.
